Abstracts tagged "systemic lupus erythematosus (SLE) and systemic sclerosis"

Abstract Number: 1961 • 2018 ACR/ARHP Annual Meeting
Association of GTF2I Region Polymorphism with Systemic Lupus Erythematosus and Systemic Sclerosis, but Not with ANCA-Associated Vasculitis and Polymyositis/Dermatomyositis, in a Japanese Population
Nozomi Yokoyama^1,2, Aya Kawasaki^1,2, Takashi Matsushita³, Hiroshi Furukawa^1,2,4, Yuya Kondo⁵, Fumio Hirano^6,7, Ken-ei Sada⁸, Isao Matsumoto⁵, Makio Kusaoi⁹, Hirofumi Amano⁹, Shohei Nagaoka¹⁰, Keigo Setoguchi¹¹, Tatsuo Nagai¹², Kota Shimada^4,13, Shouji Sugii¹⁴, Atsushi Hashimoto¹⁵, Toshihiro Matsui¹⁶, Akira Okamoto¹⁷, Noriyuki Chiba¹⁸, Eiichi Suematsu¹⁹, Shigeru Ohno²⁰, Masao Katayama²¹, Kiyoshi Migita²², Hajime Kono²³, Minoru Hasegawa²⁴, Shigeto Kobayashi²⁵, Hidehiro Yamada²⁶, Kenji Nagasaka²⁷, Takahiko Sugihara²⁸, Kunihiro Yamagata²⁹, Shoichi Ozaki²⁶, Manabu Fujimoto³⁰, Naoto Tamura⁹, Yoshinari Takasaki⁹, Hiroshi Hashimoto³¹, Hirofumi Makino³², Yoshihiro Arimura³³, Masayoshi Harigai³⁴, Shinichi Sato³⁵, Takayuki Sumida⁵, Shigeto Tohma^36,37, Kazuhiko Takehara³ and Naoyuki Tsuchiya^1,2, ¹University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, ²University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, ³Kanazawa University, Department of Dermatology, Kanazawa, Japan, ⁴National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, ⁵Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁶Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁷Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, ⁸Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan, ⁹Juntendo University, School of Medicine, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ¹⁰Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ¹¹Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, ¹²Kitasato University, Department of Rheumatology and Infectious Diseases, Sagamihara, Japan, ¹³Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ¹⁴Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ¹⁵Rheumatology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ¹⁶National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Kanagawa, Japan, ¹⁷Department of Rheumatology, Himeji Medical Center, National Hospital Organization, Himeji, Japan, ¹⁸Department of Rheumatology, Morioka Hospital, National Hospital Organization, Morioka, Japan, ¹⁹Clinical Research Institute, Department of Internal Medicine and Rheumatology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan, ²⁰Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan, ²¹Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, ²²Fukushima Medical University, School of Medicine, Fukushima, Japan, ²³Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²⁴University of Fukui, Department of Dermatology, Fukui, Japan, ²⁵Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ²⁶St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, ²⁷Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ²⁸Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²⁹University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, ³⁰University of Tsukuba, Faculty of Medicine, Department of Dermatology, Tsukuba, Japan, ³¹Juntendo University School of Medicine, Tokyo, Japan, ³²Okayama University Hospital, Okayama, Japan, ³³Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ³⁴Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ³⁵The University of Tokyo, Department of Dermatology, Tokyo, Japan, ³⁶National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ³⁷National Hospital Organization Tokyo Hospital, Sagamihara, Japan
Background/Purpose: Genome-wide association studies of systemic lupus erythematosus (SLE) in Chinese and Korean populations identified striking association with a single nucleotide polymorphism (SNP) rs73366469, located…
Abstract Number: 1966 • 2018 ACR/ARHP Annual Meeting
Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification
Guillermo Barturen¹, Sepideh Babaei², Francesc Catala-Moll³, Zuzanna Makowska², Antonio García-Gómez³, Anne Buttgereit⁴, Elena Carnero-Montoro¹, Sikander Hayat⁴, Martin Kerick⁵, Thomas Charlon⁶, David C Gemperline⁷, Lucas Le Lann⁸, Rosa Quirantes-PIné⁹, Isabel Borrás-Linares¹⁰, Brian Muchmore¹, Jorge Kageyama⁴, Javier Rodríguez-Ubreva³, Alvaro Fernández-Ochoa⁹, Pedro Carmona Sanz¹¹, Christophe Jamin⁸, Ralf Lesche², Robert J. Benschop⁷, Chris Chamberlain¹², Ernst R. Dow⁷, Tania Gomes¹, Maria Juárez¹³, Laurence Laigle¹⁴, Jacqueline Marovac¹², Fiona MacDonald¹⁵, Jerome Wojcik⁶, Esteban Ballestar¹⁶, Lorenzo Beretta¹⁷, Maria Orietta Borghi¹⁸, Johan Frostegård¹⁹, Maria Luisa Garcia²⁰, Javier Martín⁵, Jacques-Olivier Pers⁸, Yves Renadineau²¹, Antonio Segura Carretero⁹ and Marta Alarcón-Riquelme^1,19, ¹Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany, ³Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ⁴Bayer Pharma Aktiengesellschaft, Berlin, Germany, ⁵Institute of Parasitology and Biomedicine López Neyra, Spanish National Research Council, Granada, Spain, ⁶QuartzBIO, SA, Geneva, Switzerland, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ⁹Department of Analytical Chemistry, University of Granada, Granada, Spain, ¹⁰Analytical Chemistry, University of Granada, Granada, Spain, ¹¹Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB, Slough, United Kingdom, ¹⁴Institut de Recherches Internationales Servier, Suresnes, France, ¹⁵Bayer Pharma G, Berlin, Germany, ¹⁶Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ¹⁷Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁸University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹⁹Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²⁰Nano-Imaging, BIONAND. Centro Andaluz de Nanotecnología y Biomedicina, Malaga, Spain, ²¹U1227, Université de Brest, inserm, Labex IGO, CHU de brest, Brest, France
Background/Purpose: Systemic autoimmune diseases (SADs) are chronic inflammatory conditions with autoimmune aetiology and many common clinical features, difficulting diagnosis and adequate treatment decisions. Finding new…
Abstract Number: 2377 • 2018 ACR/ARHP Annual Meeting
Body Image in Rheumatic Diseases: A Systematic Review
Shadi Gholizadeh¹, Annie Meier², Sarah D. Mills³ and Vanessa L. Malcarne⁴, ¹Clinical Psychology, SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²Psychology, San Diego State University, San Diego, CA, ³Medicine, Lineberger Comprehensive Cancer Center University of North Carolina, Durham, NC, ⁴SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA
Background/Purpose: In health conditions that cause changes in appearance, especially in areas of the body that are highly visible and socially salient (e.g., face and…
Abstract Number: 1639 • 2017 ACR/ARHP Annual Meeting
Longitudinal Evolution in a Nationwide Cohort Originally Classified As Mixed Connective Tissue Disease
Silje Reiseter¹, Ragnar Gunnarsson², Jukka Corander³, Johanna Haydon⁴, May Brit Lund⁵ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, ³Departement of Biostatistics, University of Oslo, Oslo, Norway, ⁴Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁵Respiratory Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Ever since Mixed Connective Tissue Disease was presented as a distinct entity in 1972, it has been discussed whether MCTD represents an undifferentiated, transient…
Abstract Number: 2008 • 2017 ACR/ARHP Annual Meeting
“Intrathoracic Manifestations of Connective Tissue Diseases on High Resolution Computed Tomography”
Diego Baenas¹, Maira Orozco², María Eugenia Olmos³, Luis Lasca⁴, Paula Riba⁵, Patricio Muszinsky⁵, Juan Pablo Pirola⁶, Verónica Saurit⁷, Alejandro Alvarellos⁷, Ana C. Alvarez⁸, Soledad Retamozo^9,10, Nadia Riscanevo^7,11, Janet Flores¹², Ariel Blua³, Ana María López¹³, Gustavo Muiño¹⁴, Santiago Orozco¹⁵ and Francisco Caeiro¹⁶, ¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Postgraduate Career of Rheumatology Catholic University of Córdoba., Cordoba, Argentina, ²Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³Pulmonary, Pulmonary Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁴Radiology Unit, Oulton Institute, Cordoba, Argentina, ⁵Radiology, Radiology Unit, Oulton Institute, Cordoba, Argentina, ⁶Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ⁷Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁸Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ¹⁰Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ¹¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹²Rheumatology Unit, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹³Pulmonary Unit, Pulmonary Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁴Radiology, Radiology Unit,Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁵Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁶Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina
Background/Purpose: Connective tissue diseases (CTD) can cause intrathoracic involvement, increasing patients morbidity and mortality. High-resolution computed tomography (HRCT) is a key method for evaluation of…
Abstract Number: 2681 • 2017 ACR/ARHP Annual Meeting
Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome
Samar Alharbi¹, Zareen Ahmad², Zahi Touma³, Arthur Bookman⁴, Jorge Sánchez-Guerrero⁵ and Sindhu Johnson⁶, ¹Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health System, University Health Network,, Toronto, ON, Canada, ²Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁶Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health Systems and University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is an immune disorder characterized by vasculopathy and fibrosis. SSc may overlap with another disease such as systemic lupus erythematosus (SLE).…
Abstract Number: 2964 • 2015 ACR/ARHP Annual Meeting
Influences of Various Factors on Survival of Patients Treated with Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Patients with Connective Tissue Diseases
Sumiaki Tanaka¹, Yu Matsueda², Eisuke Ogawa¹, Jun Okada³ and Shunsei Hirohata¹, ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Rheumatology and Infectious diseases, Kitasato University School of Medicine, Kanagawa, Japan, ³Rheumatology, Kitasato University Hospital, Sagamihara, Japan
Background/Purpose: In patients with connective tissue disease (CTD), especially systemic sclerosis (SSc), several mechanisms have been implicated for the development of pulmonary hypertension (PH), including…
Abstract Number: 1880 • 2015 ACR/ARHP Annual Meeting
Circulating Microparticle Populations May Differentiate Between Connective Tissue Diseases.
Eoghan M. McCarthy^1,2, Daniel Moreno-Martinez³, Fiona Wilkinson⁴, Neil J McHugh^5,6, Ian N. Bruce^7,8, Yvonne Alexander³, John D. Pauling^6,9 and Ben Parker^7,8, ¹The University of Manchester, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, Mmanchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Rheumatology, Bath Institute of Rheumatic Diseases, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁶Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁷Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁸Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁹Upper Borough Walls, Royal National Hospital for Rheumatic Disease, Bath, United Kingdom
Background/Purpose: Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). Circulating MPs levels are altered…
Abstract Number: 2588 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies
Vincent Sobanski¹, Bernadette Lynch², Benjamin E. Schreiber³, Svetlana I. Nihtyanova⁴, Jennifer Harvey⁵, Clive Handler⁶, Christopher P. Denton⁷ and John G. Coghlan⁸, ¹Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ²Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ³Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ⁴Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁵Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁶Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ⁷Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁸National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of morbidity and mortality in patients with connective tissue diseases (CTD). Patients with anti-U1-RNP antibodies belong to…
Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting
Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry
Kwi Young Kang¹, Chan Hong Jeon², Sung Jae Choi³, Seung-Ki Kwok⁴, Seong-Kyu Kim⁵, Hyoun-Ah Kim⁶, Eon Jeong Nam⁷, Yong-Beom Park⁸, Kichul Shin⁹, Jaejoon Lee¹⁰, Chang-Hoon Lee¹¹, Chan-Bum Choi¹², Shin-Seok Lee¹³ and Dae-Hyun Yoo¹⁴, ¹Rheumatology, Internal Medicine, Catholic University of Korea, Incheon St. Mary's Hospital, Seoul, South Korea, ²Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ³Rheumatology, Korea University Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁷Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ⁸Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁹Rheumatology, College of Medicine, Seoul National University, Seoul, South Korea, ¹⁰Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹¹Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ¹²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ¹³Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ¹⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…
Abstract Number: 680 • 2012 ACR/ARHP Annual Meeting
Plasma Level of Galectin-3 Binding Protein Reflects Type I Interferon Activity and Is Highly Increased in Patients with Systemic Lupus Erythematosus
Christoffer T. Nielsen¹, Ole Østergaard², Line V. Iversen³, Christian Lood⁴, Anders A. Bengtsson⁴, Anne Voss⁵, Søren Jacobsen⁶ and Niels H. H. Heegaard³, ¹Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, ³Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁴Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ⁵Dept of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁶Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: Ongoing production of type I interferons (IFN) is a key element in the pathogenesis of systemic lupus erythematosus (SLE). Type I IFNs trigger the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].